1. Home
  2. CURI vs IMUX Comparison

CURI vs IMUX Comparison

Compare CURI & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CuriosityStream Inc.

CURI

CuriosityStream Inc.

SELL

Current Price

$2.75

Market Cap

165.0M

ML Signal

SELL

Logo Immunic Inc.

IMUX

Immunic Inc.

BUY

Current Price

$6.56

Market Cap

155.8M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CURI
IMUX
Founded
N/A
2016
Country
United States
United States
Employees
N/A
66
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.0M
155.8M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
CURI
IMUX
Price
$2.75
$6.56
Analyst Decision
Buy
Strong Buy
Analyst Count
3
12
Target Price
$5.33
★ $43.09
AVG Volume (30 Days)
★ 513.7K
408.2K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
★ 12.27%
N/A
EPS Growth
★ 54.17
38.00
EPS
★ 0.12
N/A
Revenue
★ $78,043,000.00
N/A
Revenue This Year
$10.59
N/A
Revenue Next Year
$12.05
N/A
P/E Ratio
$23.08
★ N/A
Revenue Growth
★ 9.52
N/A
52 Week Low
$2.30
$0.51
52 Week High
$5.10
$17.43

Technical Indicators

Market Signals
Indicator
CURI
IMUX
Relative Strength Index (RSI) 43.44 22.68
Support Level $2.32 $0.83
Resistance Level $2.97 $15.82
Average True Range (ATR) 0.10 0.65
MACD -0.03 -0.02
Stochastic Oscillator 11.63 0.00

Price Performance

Historical Comparison
CURI
IMUX

About CURI CuriosityStream Inc.

CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: